Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Traws Pharma (TRAW) Return on Sales (2016 - 2025)

Traws Pharma's Return on Sales history spans 14 years, with the latest figure at 6.41% for Q4 2025.

  • Quarterly results put Return on Sales at 6.41% for Q4 2025, up 8784.0% from a year ago — trailing twelve months through Dec 2025 was 6.41% (up 62357.0% YoY), and the annual figure for FY2025 was 6.41%, up 62357.0%.
  • Return on Sales for Q4 2025 was 6.41% at Traws Pharma, down from 5.55% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.46% in Q2 2025 to a low of 2164.0% in Q2 2024.
  • The 5-year median for Return on Sales is 81.18% (2023), against an average of 180.17%.
  • The sharpest move saw Return on Sales tumbled -208312bps in 2024, then skyrocketed 216354bps in 2025.
  • Year by year, Return on Sales stood at 67.2% in 2021, then plummeted by -52bps to 102.39% in 2022, then increased by 22bps to 79.68% in 2023, then dropped by -18bps to 94.25% in 2024, then skyrocketed by 93bps to 6.41% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 6.41%, 5.55%, and 0.46% for Q4 2025, Q3 2025, and Q2 2025 respectively.